Glial fibrillary acidic protein: A marker of axonal Guillain–Barrè syndrome and outcome
✍ Scribed by Francesca Notturno; Christina M. Caporale; Angelo De Lauretis; Antonino Uncini
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 100 KB
- Volume
- 38
- Category
- Article
- ISSN
- 0148-639X
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract We evaluated serum glial fibrillary acidic protein (GFAP) levels by enzyme‐linked immunosorbent assay (ELISA) in controls (__n__ = 30) and in patients with chronic sensory‐motor axonal neuropathy (CSMAN) (__n__ = 30), chronic inflammatory demyelinating polyneuropathy (CIDP) (__n__ = 30)
and the Plasma Exchange/Sandoglobulin Guillain-Bard Syndrome Trial Group7 We performed electrophysiological and serological testing within 15 days of symptom onset on 369 patients with Guillain-Bark Syndrome (GBS) enrolled in a trial comparing plasma exchange, intravenous immunoglobulin, and both t
## Abstract Glial fibrillary acidic protein (GFAP) is the principal component of the intermediary filaments in mature astrocytes of the central nervous system (CNS). The protein consists of three domains: the head, the coiled‐coil, and the tail. Here, we describe the isolation of an evolutionary co
## Abstract A retrospective study of 366 primary brain tumours in childhood has been carried out. GFAP was detected in juvenile astrocytoma (76/121), adult astrocytoma (34/78), malignant glioma (0/8), other astrocytic tumours (2/4) and medulloblastoma (0/101). In eight medulloblastomas scanty posit